Navigation Links
Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
Date:2/2/2009

ellular level. After protective antigen and the anthrax toxins are produced by the bacteria, protective antigen binds to the anthrax toxin receptor on cell surfaces and forms a protein-receptor complex that makes it possible for the anthrax toxins to enter the cells. ABthrax blocks the binding of protective antigen to cell surfaces and prevents the anthrax toxins from entering and killing the cells.

In contrast to the anthrax vaccine, the protection afforded by a single dose of ABthrax would be immediate following the rapid achievement of appropriate blood levels of ABthrax. In contrast to antibiotics, ABthrax acts against the deadly toxins produced by anthrax bacteria. It may also prevent and treat infections by antibiotic-resistant strains of anthrax. ABthrax was the first investigational agent against anthrax infection to be evaluated in a clinical study following the 2001 anthrax attacks in the United States. In 2003, ABthrax received a Fast Track Product designation from the FDA, as well as an Orphan Drug Designation for its use in the treatment of inhalation anthrax disease.

About the ABthrax Contract with the U.S. Government

In June 2006, the U.S. Government exercised its option to purchase ABthrax for the Strategic National Stockpile (Contract Number HHS010020050006C). HGS expects to receive $165 million in revenues from this award, with $150 million to come in the first half of 2009, following delivery of 20,000 doses of ABthrax, and the remainder to come upon FDA licensure of ABthrax. The purchase award was made by the HHS under the Project BioShield Act of 2004, which is designed to accelerate the development, purchase and availability of medical countermeasures for the Strategic National Stockpile. Under the contract, HGS has manufactured and is now delivering 20,000 treatment courses of ABthrax to the Stockpile. Also under the contract, the Company plans to file a Biologi
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Mardil Inc. Advances Its Novel Cardiac Device to First-In-Human Trials for Mitral Valve Regurgitation
2. Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
3. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
4. Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference
5. 2008 Human Research Protection Award Recipients Announced
6. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
7. Vical Pandemic Influenza Vaccines Achieve T-Cell Responses and Cross-Clade Reactivity in Humans
8. SARS Vaccine Achieves Neutralizing Responses in First U.S. Human Trial
9. GeoVaxs Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America
10. Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
11. Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 ... stage. Growing ageing population and rise in the incidence ... of chronic wounds and in affordability of better quality ... Chinese wound care market. Universal coverage of public health ... products would further stimulate demand. Based on the findings ...
(Date:9/30/2014)... 30, 2014  Based on its recent analysis ... Sullivan recognizes Ventana Medical Systems, Inc. (Ventana), a ... North American Frost & Sullivan Award for Technology ... with a focus on innovation and improving patient ... tissue-based cancer diagnostic solutions for patients worldwide. ...
(Date:9/30/2014)... Passport Health, one of the largest immunizers ... FluFree.com, a website designed to promote, educate about, and ... years, Passport Health has provided its clients with protection ... FluFree.com is designed to address the growing gap between ... who actually chose to get vaccinated. "We ...
Breaking Medicine Technology:China Wound Care Market 2China Wound Care Market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4Passport Health Launches FluFree.com - Aims To Improve Flu Vaccination Rates and Fulfill Growing Public Health Priority 2Passport Health Launches FluFree.com - Aims To Improve Flu Vaccination Rates and Fulfill Growing Public Health Priority 3
... WIRE)--May 10, 2007 - An evaluation of the,safety ... the,treatment of vaginal atrophy, a frequent complaint of,postmenopausal ... American,Menopause Society (NAMS). Entitled "The role of local ... women:,2007 position statement of The North American Menopause ...
... Technology Demonstrates Novel,Anti-Inflammatory Properties, New Surfaxin ... Academic,Societies Annual Meeting , WARRINGTON, Pa., ... Discovery,Laboratories, Inc. (Nasdaq:DSCO) announced that new ... novel KL-4 surfactant,(lucinactant) replacement technology were ...
Cached Medicine Technology:New Position Statement from The North American Menopause Society,Addresses Use of Local Estrogen for Treatment of Vaginal Atrophy in,Postmenopausal Women 2New Position Statement from The North American Menopause Society,Addresses Use of Local Estrogen for Treatment of Vaginal Atrophy in,Postmenopausal Women 3Discovery's KL-4 Surfactant Technology Demonstrates Novel,Anti-Inflammatory Properties 2Discovery's KL-4 Surfactant Technology Demonstrates Novel,Anti-Inflammatory Properties 3Discovery's KL-4 Surfactant Technology Demonstrates Novel,Anti-Inflammatory Properties 4Discovery's KL-4 Surfactant Technology Demonstrates Novel,Anti-Inflammatory Properties 5Discovery's KL-4 Surfactant Technology Demonstrates Novel,Anti-Inflammatory Properties 6
(Date:9/30/2014)... NJ (PRWEB) September 30, 2014 ... and wellness, is opening another new medical specialty practice ... IMA Cardiology will be located within the ... Ziad Abbud and Dr. Isaac Tawfik of American Heart ... N.J. The new practice will offer Integrated Medicine Alliance ...
(Date:9/30/2014)... research team has been awarded a three-year $1.7 ... (NIH) to develop new imaging technologies and data ... how large networks of neurons in the brain ... help researchers identify the precise interactions between millions ... and speaking, and alterations in these interactions that ...
(Date:9/30/2014)... 30, 2014 Elevate , the latest ... better in and out of the gym by providing natural ... the attention of Shane Michaels, prompting an investigative review. ... the reason most people simply just don’t have the ability ... focused at work, getting the motivation to finish a project, ...
(Date:9/30/2014)... 2014 Hospice & Palliative Care ... Celebration” gala, honoring three outstanding individuals for their ... to provide extraordinary and dignified comfort, care and ... or life-limiting illness. , The event was held ... and recognized William (Bill) J. McGuinness, Director of ...
(Date:9/30/2014)... Dr. Karl R.O.S. Johnson, DC, has developed ... care that is dramatically improving the health and lives ... & Nutrition—applies a proprietary, multi-dimensional approach that goes beyond ... of inflammation, neurology of the joint and neurology of ... brain to the spine, to the legs, knees and ...
Breaking Medicine News(10 mins):Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 3
... neuropathy than blood glucose levels, study suggests , , THURSDAY, ... levels of triglyceride fats are at increased risk of ... or damage of nerves that results in numbness, tingling ... researchers say. , A study by U.S. researchers ...
... 2009 In an effort that will contribute ... and the surrounding region, the country,s National Center ... Calidad (CNCC)has attained internationally recognized ISO/IEC 17025:2005 accreditation ... being celebrated today in Lima by the CNCC ...
... NEW YORK, May 21 The Journal of Visual ... on blindness and visual impairment from AFB Press, is now ... access and $65 for a combined print and online subscription."For ... of the field,s literature by keeping professionals and students up-to-date ...
... HealthEast Care System hospitals have agreed to pay ... that the health care facilities submitted false claims ... three hospitals are located in the Minneapolis-St. Paul, ... Paul-based hospitals overcharged Medicare from 2002 to 2007 ...
... According to a new Mayo Clinic study, a history ... challenges facing depressed inpatients. Included are an increase in ... higher incidence rate of personality disorder. Additionally, these victims ... an increase in psychiatric hospitalizations for psychiatric issues. The ...
... May 21 Mayo Clinic researchers have found that ... such as diabetes, depression, asthma or coronary artery disease. ... care claim costs. Specialty care costs (the costs of ... higher for bipolar patients. Results of this review are ...
Cached Medicine News:Health News:High Blood Fats Tied to Diabetic Nerve Loss 2Health News:Medication quality in Peru and region strengthened with official laboratory's accreditation 2Health News:New Reduced Subscription Rate to Leading International Journal on Blindness and Low Vision 2Health News:Minnesota Hospitals to Pay U.S. $2.28 Million to Settle False Claims Act Allegations 2Health News:Specialty Care Costs for Patients With Bipolar Disorder Are Higher Than Diabetes and Other Chronic Diseases 2
Straight shafts with fine pierse type tips. Flat open serrated handle with dull finish....
Straight shafts with two point fixation. Tips separated by 3 mm, each tip has 0.12 mm, 1 x 2 teeth. Wide serrated handle with dull finish....
Straight shafts with micro Pierse type tips. Flat open serrated handle, dull finish....
Straight shafts with 25 degree angled 1.5 mm tips. 4 mm platform with 0.12 mm, 1 x 2 teeth. Wide serrated handle with polished finish....
Medicine Products: